Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors
详细信息 查看全文
- 作者：Rossana MaffeiAuthor Vitae ; Elisabetta ColaciAuthor Vitae ; Stefania FiorcariAuthor Vitae ; Silvia MartinelliAuthor Vitae ; Leonardo PotenzaAuthor Vitae ; Mario LuppiAuthor Vitae ; Roberto Marasca ; roberto.marasca@unimore.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae
- 关键词：Chronic lymphocytic leukemia ; Lenalidomide ; Clinical efficacy ; Immune activation ; Microenvironment ; Response prediction
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：97
- 期：Complete
- 页码：291-302
- 全文大小：1515 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Lenalidomide is a drug clinically active in CLL and with manageable toxicity.
- class="label">•
Lenalidomide targets both CLL cells and their interactions with microenvironment.
- class="label">•
Lenalidomide counteracts the immunosuppressive attitude of CLL microenvironment.
- class="label">•
Lenalidomide could be a core platform for combinations with new TKIs in CLL.